Skip to main content
. 2019 Dec 30;318(2):H378–H390. doi: 10.1152/ajpheart.00302.2019

Fig. 2.

Fig. 2.

Inhibition of activin type II receptor (ACTRII)/TGFβ receptor (TGFBR) signaling is associated with preserved cardiac function and exercise tolerance. A: change in fractional shortening (FS) from 2 wk after LAD surgery to the end of treatment/vehicle (10 wk after surgery) in sham and mice with myocardial infarction (MI) treated with vehicle, Myo-Fc, or a combination of follistatin and a TGFβ receptor inhibitor (Fol + TGFi); n ≥ 10 mice/group. B and C: representative echocardiography M-mode images (B) and table showing absolute FS in sham and MI mice before and after treatment (C). D: running time (min) in running endurance test at increasing speed at the end of treatment/vehicle (10 wk after surgery) in sham and mice with myocardial infarction (MI) treated with vehicle or Myo-Fc; n ≥ 10 mice/group. E and F: cardiac mRNA levels of BNP (E) and ANP (F); n = 5 mice/group. *P < 0.05 by 2-way ANOVA (A, E, and F) or log rank test (D).